CVI
Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Bakshi, S. S.
Right arrow Articles by Pahwa, S. G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Bakshi, S. S.
Right arrow Articles by Pahwa, S. G.

Clinical and Diagnostic Laboratory Immunology, January 1998, p. 38-40, Vol. 5, No. 1
1071-412X/98/$04.00+0
Copyright © 1998, American Society for Microbiology. All rights reserved.

Distribution of CCR5Delta 32 in Human Immunodeficiency Virus-Infected Children and Its Relationship to Disease Course

Saroj S. Bakshi,1 Linqi Zhang,2 David Ho,2 Soe Than,1 and Savita G. Pahwa1,*

Department of Pediatrics, Division of Immunology, North Shore University Hospital-New York University School of Medicine, Manhasset,1 and The Aaron Diamond AIDS Research Center, Rockefeller University, New York,2 New York

Received 23 July 1997/Returned for modification 3 September 1997/Accepted 9 October 1997

Homozygosity for a 32-bp deletion in the CCR5 gene (CCR5Delta 32) has been shown to confer resistance to infection with the macrophage-tropic strain of human immunodeficiency virus (HIV) type 1. We examined the distribution of CCR5Delta 32 in 47 children (age range, 1.5 to 19 years), of whom 43 were infected with HIV, by the perinatal route (n = 41) or by the intravenous route (n = 2). The infected patients were classified as rapid progressors (RP) (n = 7) (CDC category C3 or death by 2 years of age), non-rapid progressors (NRP) (n = 17) (survival for >= 8 years after infection), or intermediate (n = 19). CCR5Delta 32 heterozygosity was found in two HIV-infected children, both NRP. None of the subjects were homozygous for CCR5Delta 32, and the remaining children had no evidence of CCR5Delta 32. The presence of CCR5Delta 32 heterozygosity in 4.8% of this, predominantly non-Caucasian population is consistent with the published distribution of the mutation. The finding that CCR5Delta 32 was present only in NRP and not in any RP is in agreement with previous reports suggesting that heterozygosity for CCR5Delta 32 may confer limited protection from disease progression.


* Corresponding author. Mailing address: 350 Community Dr., Manhasset, NY 11030. Phone: (516) 562-4641. Fax: (516) 562-2866. E-mail: spahwa{at}nshs.edu.


Clinical and Diagnostic Laboratory Immunology, January 1998, p. 38-40, Vol. 5, No. 1
1071-412X/98/$04.00+0
Copyright © 1998, American Society for Microbiology. All rights reserved.






Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
Antimicrob. Agents Chemother. Clin. Microbiol. Rev. Infect. Immun.
J. Clin. Microbiol. J. Virol. ALL ASM JOURNALS

Copyright © 1998 by the American Society for Microbiology. All rights reserved.